Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmacoeconomics
Päätekijät: Blommestein, Hedwig M., Armstrong, Nigel, Ryder, Steve, Deshpande, Sohan, Worthy, Gill, Noake, Caro, Riemsma, Rob, Kleijnen, Jos, Severens, Johan L., Al, Maiwenn J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2015
Aiheet:
Review Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4706836/
https://ncbi.nlm.nih.gov/pubmed/26314282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0318-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia